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A B S T R A C T
Background: Prevention of arthropod-borne infections hinges on bite prevention. We aimed to investigate tra-
vellers’ use of repellents.
Methods: We measured the amount of applied repellent with a spray containing 30% DEET and 20% Icaridin
versus a lotion with 20% Icaridin alone. We calculated the concentration of active ingredient reached on the skin
and evaluated formulation acceptability. The travellers completed a questionnaire evaluating Knowledge,
Attitudes and Practice (KAP) to anti-vectorial protective measures (AVPM).
Results: Some 200 volunteers travelling to mosquito borne infection endemic areas were recruited. The mean
concentration of active substance achieved on the skin of the left arm was 0.52mg/cm2 of DEET/Icaridin spray
versus 0.21 mg/cm2 of Icaridin lotion. These levels are below the recommended protective dose (1mg/cm2) for
each formulation. Women were signiﬁcantly more likely to apply a higher, protective dose of repellent.
Travellers to Africa, women and older participants showed higher projected adherence to AVPM.
Conclusions: Only 2.5% of recruited travellers applied the recommended protective dose of repellent. Women
and older travellers are the most adherent users of repellents. The pre-travel health consultation should provide
more information on the application quantity and correct use of repellents.
1. Background
Mosquito borne infections such as malaria, dengue, chikungunya,
Zika and Japanese encephalitis have an expanding geographic range
worldwide. They constitute an important global burden of disease with
signiﬁcant mortality, morbidity and long-term illness sequelae that af-
fect hundreds of millions of people living in endemic areas [1]. Tra-
vellers visiting aﬀected areas are challenged as there are few traveller
vaccines available, with the exception of Japanese encephalitis, and
most protective approaches rely on the prevention of mosquito and
arthropod bites [2].
Use of repellents is a key measure in the prevention of mosquito
bites. A repellent is deﬁned as a “chemical volatile substance that in-
duces arthropods to move in the opposite direction from its source” [3].
Repellents are volatile, usually oily substances whose odour prevents
the landing of mosquitoes and other arthropods on the skin. An ideal
repellent should protect against a wide variety of arthropods for several
hours and withstand removal when sweating, rubbing or washing
without causing adverse events nor damage clothes or accessories (e.g.
bracelets, watches, eyeglass frames) [3,4]. Mosquitoes are still attracted
by humans after repellent application, however the mosquitoes are
repelled when coming close because of the volatile ingredients of the
repellent. This protective air layer extends only for a few centimetres,
therefore the repellent has to be applied all-over the exposed skin [5,6].
N,N-Diethyl-3-methylbenzamide (DEET, formerly N,N-Diethyl-m-
toluamide), developed by the United States Department of Agriculture
and on the market since 1957, is considered to be the most eﬀective and
widely used repellent worldwide [7]. It is also used as the standard
reference repellent of the WHO [8,9]. DEET is a synthetic, oily and
volatile liquid, insoluble in water, but very soluble in alcohol. The re-
pelling eﬀect of DEET is a result of its aﬃnity and binding to odorant
receptors as well as to chemoreceptors of the mosquitoes [10]. The
eﬃcacy of repellents containing DEET has been shown in both la-
boratory conditions and ﬁeld studies not only against mosquitoes, but
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also against many other blood-feeding arthropods such as black ﬂies,
ticks and leeches [6,11]. The most frequently observed adverse events
associated with DEET are mild skin irritations. There have been some
reports of encephalopathy after DEET exposure, notably in children
after ingestion, but also after dermal exposure [12]. However, the
causal role of DEET in these cases is debatable and taking into account
the extensive use of DEET worldwide (approximately 200 million ap-
plications per year), the number of reported adverse events is low
[13–15]. Risk assessments by the US Environmental Protection Agency
(EPA) as well as a clinical trial found no connection between en-
cephalopathy and use of DEET, and no toxic risk or severe eﬀects except
after inappropriate use (ingestion, direct inhalation, or eye exposure)
[15]. After dermal application, low levels of DEET and its metabolites
were detected in blood plasma. However, less than 9% of the amount
applied was absorbed [16]. DEET can also cross the placenta, but a
small study of DEET exposure (1.7g/day) in second and third trimester
pregnancies in Thailand did not detect adverse eﬀects in either exposed
women or infants [17]. DEET is considered to be safe from second
trimester onwards, while breast-feeding and for children aged over 8
weeks [18], but recommendations regarding the use of DEET for chil-
dren vary by country. Furthermore, there are no published data on the
use and tolerability of DEET by pregnant women in the ﬁrst trimester.
In general for travellers, formulations with concentrations of 20% DEET
and higher are considered to provide good and long lasting protection
[19].
Icaridin (also known as Picaridin, Bayrepel, KBR3023) is a syn-
thetic, volatile, and water-insoluble oily repellent. It is almost as ef-
fective as DEET and shows a lower rate of adverse events [20]. Adverse
events reported to the National Poison Data System included ocular
irritation, reddened eyes, vomiting, and oral irritation. Symptoms were
usually mild and no serious adverse events (life threatening, hospita-
lization required, or persistent disability) or cases of death were re-
ported [21]. Formulations on the market usually contain from 5% up to
30% Icaridin, while a higher concentration provides a longer lasting
protection [6]. Icaridin is supposed to bind to the same or similar ol-
factory receptors and chemoreceptors as DEET [22].
To provide a good protection, repellents should be applied in a
suﬃcient amount on the skin. Rutledge and Colleagues developed a
mathematical model to describe the persistence and eﬀectiveness of
repellents on the skin over 30 years ago [23]. The duration of the
protection rises with the applied dose of active ingredient and reaches a
plateau at a skin concentration of 2mg/cm2. A dose above 1mg/cm2 is
considered to provide a reasonable and long lasting protection i.e.
several hours under laboratory conditions [24]. In studies evaluating
lower doses of active ingredients, protection levels were suﬃcient in
the ﬁrst hour after application, but then decreased slowly [6,25]. The
WHO guidelines for eﬃcacy testing recommend a dose of 1ml of pro-
duct for 600 cm2 (approximately 1.67mg/cm2) without considering the
concentration of active ingredient [8]. This reference dose is used by
default in laboratories evaluating repellents. The American guidelines
from the EPA do not recommend a standard dose for application. The
products are applied ad libitum and the mean dose is measured [26].
A study from the UK with 74 participants living in the UK and 54
travellers to Kenya and India showed that repellent users rarely
achieved the required protective concentration of 1mg/cm2 DEET. On
the neck and on the arms the achieved skin concentration was below
the required concentration [27]. Another study from the UK showed
that the amount applied was greater when participants used a lotion
compared to using a spray. However, the number of participants in that
evaluation was very small (n= 12) and the results may not be re-
presentative [28].
A major issue for travellers is the adherence with repellents and
other anti-vectorial protective measures (AVPM). A study among
United States Community Service Volunteers returning from the
Dominican Republic showed rather good adherence to AVPM. More
than 90% used repellents and a bed net [29]. However, another
American study with the Department of Defence beneﬁciaries travelling
to regions for vector borne diseases showed a rather poor overall
compliance with AVPM. 53% used skin repellents, 16% used perme-
thrin on clothing and 39% used a bed net [30]. Similar or even poorer
compliance rates have been shown in other studies with civil travellers
[31,32]. The recommendations for the quantitative use of repellents
provided by the manufacturers on the product packaging are very
limited and therefore may not contribute to appropriate application
doses and rates.
The aim of this study was to measure, quantitatively, the amount of
repellent applied to the arm with two diﬀerent application forms
(spray, lotion) as well as to evaluate the knowledge, attitude and
practice of traveller, with regard to bite protection and their intended
AVM approaches when visiting regions endemic for mosquito borne
infections.
2. Methods
2.1. Study design
This study was carried out from April until June 2018 with 200
subjects (99 male and 101 female subjects) recruited from clients at-
tending the Centre for Travel Medicine of the University of Zurich,
WHO Collaborating Centre for Travellers’ Health, who were going to
regions endemic for mosquito borne infections. The study participants
were informed about the study in order of arrival at the travel clinic
while they waited for their pre-travel consultation in the waiting room.
All persons who gave informed consent (approximately 50% of those
asked) were included into the study. The exact response rate was not
recorded. The recruitment was stratiﬁed in order to obtain equal
numbers of males and females for the study and within repellent
groups. Two repellents, a spray containing 30% DEET and 20% Icaridin
(Nobite® extreme) and a lotion containing 20% Icaridin (not yet mar-
keted), were compared with regard to the applied dose, tolerability, and
usability of the products. The repellents were provided in neutral
containers without brand names. The subjects were randomised into
two equally sized and gender balanced groups each applying one of the
repellents. They were asked to apply the repellent on their left arm
without any further instructions. The dose applied was estimated by
measuring the loss of weight of the repellent container and the con-
centration of the active ingredient on the skin was calculated according
to the formula described by Goodyer and Patel (Fig. 1) [28].
After the application of the repellents, the subjects were asked to
complete a questionnaire about the tolerability and usability of the
applied repellents and about their knowledge, attitude, and practice
(KAP) of AVPM in general. Yes-no questions were used to evaluate
adverse events of the repellents. To rate the user acceptability and the
odour of the repellents, visual analogue scales were used. To evaluate
the KAP, the subjects could choose from given answers. The subjects
were recruited before receiving pre-travel health advice at the travel
clinic.
2.2. Sample size considerations
The sample size calculation used the amount of repellent applied as
primary outcome. Data for sample size calculation was taken from the
study by Thrower and Goodyer [27]. The sample size calculation based
on a between-group diﬀerence in the primary outcome of 0.12mg/cm2,
an anticipated standard deviation of 0.29, a signiﬁcance level of 5% and
power of 80%. This sample size calculation resulted in 75 persons per
group, the group size was increased to 100 persons per group to ensure
equal numbers of both sexes.
2.3. Statistical analysis
The software Stata (Version 13.1) was used for the data analysis.
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Descriptive statistics included mean and standard deviation for the
continuous variables, as well as counts and percentage of total for the
categorical variables. Ordinally scaled variables were displayed as
median and interquartile range. T-test and ANOVA were used to com-
pare the amount of repellents applied across randomized groups.
Fisher's exact tests or chi square tests were performed for the analysis of
the KAP questionnaire. The p-values for adverse events and KAP
questionnaire were considered exploratory. Other p-values< 0.05 were
considered as statistically signiﬁcant.
2.4. Ethical considerations
The protocol synopsis of this study was reviewed by the Cantonal
Ethics Committee of Zurich (BASEC Request-Nr. Req-2018-00139). The
project did not fall within the scope of the Human Research Act (HRA)
since repellents are classiﬁed as cosmetic products in Switzerland.
Therefore, no formal ethics committee approval was required. Each
participant signed an informed consent form at the beginning of the
study after a thorough explanation of the study's procedures and ob-
jectives.
3. Results
3.1. Study population
In total, 200 subjects, 99 male and 101 female persons, were re-
cruited prior to receiving pre-travel advice and included in this study.
The mean age was 35 years. The range was from 18 to 70 years. With
regard to the age distribution, 89 (44.5%) of the participants were
younger than 30 years, 54 (27%) were aged between 30 and 40 years,
and 57 (28.5%) were 40 years or older. Slightly less than half of the
participants 99 (49.5%) were male. South America and South East Asia
were the most popular travel destinations with 64 (32%) respectively
63 (31.5%) travellers. 28 (14%) travellers were going to East Africa and
13 (6.5%) to West Africa, the high-risk malaria regions. For 170 (85%)
subjects, the main purpose of their trip was leisure/tourism, 16 (8%)
were visiting friends and relatives (VFR), 14 (7%) were going on a
business trip. 136 (68%) had previously visited countries endemic for
mosquito borne infections (Table 1).
3.2. Repellents
Only 5 subjects (2.5%), solely in the group using the formulation of
DEET plus Icaridin, achieved the protective levels of 1mg/cm2 active
ingredient proposed by Buescher and Rutledge [24]. The mean dose of
repellent applied on the left arm was 1.04mg/cm2 of DEET/Icaridin
spray (corresponding to active substance concentration of 0.52mg/
cm2) versus 1.07mg/cm2 of Icaridin lotion (active substance con-
centration of 0.21mg/cm2) (Table 2). Hence, the subjects did not apply
more of the repellent when using a lotion compared to a spray
(p= 0.389).
In general, women applied a higher dose compared to men. In the
DEET/Icaridin spray group, women applied 0.37mg/cm2 more than
men (p= 0.020). In the Icaridin lotion group, the diﬀerence was
0.14mg/cm2 (p= 0.138) (Table 2).
Regarding the active ingredients, subjects using the DEET/icaridin
spray (50% active ingredients) reached a mean concentration of
0.52mg/cm2, whereas subjects using the icaridin lotion (20% active
ingredient) reached only 0.21mg/cm2 (p=<0.001) (Figs. 2 and 3).
Regarding the age, subjects were grouped into three categories
(18–29, 30–39, and 40 + years). In the age group 40+, the applied
dose was highest (1.36 mg/cm2 DEET/Icaridin spray; 1.22mg/cm2
Icaridin lotion), followed by the youngest group 18–29 (1.0mg/cm2
DEET/Icaridin spray; 0.95mg/cm2 Icaridin lotion). The group aged
30–39 years applied the lowest doses (0.8 mg/cm2 DEET/Icaridin
spray; 1.11mg/cm2 Icaridin lotion). However, the diﬀerences between
the age groups were not signiﬁcant (DEET/Icaridin spray group:
p=0.069, Icaridin lotion group: p=0.192) (Table 2).
No serious adverse events were reported. Six subjects in the DEET/
Icaridin spray group and six in the Icaridin lotion group had a burning
sensation on the skin after the application. One participant in the
DEET/Icaridin spray group had a reddening of the skin compared to
three in the Icaridin lotion group (p= 0.621). Four subjects, only in the
DEET/Icaridin spray group, felt a burning sensation in the airways
(p= 0.121). 48 participants in the DEET/Icaridin spray group de-
scribed a sticky feeling on the skin and 41 in the Icaridin lotion group
(p= 0.319) following application of the repellent (Table 3).
There was no diﬀerence between the two repellents with regard to
the odour, both reached mean marks of 3.09 out of 5 (1= unpleasant,
5= pleasant) on the visual analog scale. The usability of the DEET/
Icaridin spray was slightly better rated with 1.35 (1= easy to use,
5= complicated to use) compared to the Icaridin lotion with 1.52
Fig. 1. Calculation of the amount of repellent applied on the left arm*.
* Formula proposed by Goodyer and Patel [28].
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(Table 3).
3.3. Knowledge, attitude, and practice
Six men (6%) stated that they would never use repellents on their
trip. 45 subjects (22.6%) intended to use them once per day, 95 (47.7%)
twice per day, 41 (20.6%) every 5 h and 12 (6%) every 3 h. In general,
women intended to use the repellents more often per day than men
(Table 4). Most of the participants (126, 63%) intended to use the re-
pellents during day- and night-time, 41 (20.5%) only during night-time
and 27 (13.5%) only during daytime. 154 (77%) planned to use further
measures against mosquito bites, among which the most mentioned
were long sleeved clothes (55%) and mosquito nets (46%). 88 (87.1%)
women intended to use further measures, compared to 66 (66.7%) men
(p=0.001) (Table 5).
Regarding the travel destinations and the intended use of additional
anti-vectorial prevention measures, travellers to East Africa, West
Africa, and Southern Africa stated the highest projected adherence
rates. Travellers to South America and South East Asia showed lower
projected adherence rates, travellers to Central America and Middle
East had the lowest projected adherence rates (Table 6).
The subjects in the oldest age group (40 + years old) showed the
highest projected adherence rates with regard to the use of additional
mosquito bites prevention measures (49; 86%), followed by group
30–39 (43; 79.6%) (p = 0.064). The youngest group showed the
poorest projected rates (62; 69.7%). Tourists and subjects visiting
friends and relatives stated similar projected adherence rates (129;
75.9% respectively 12; 75%). Business travellers had a higher projected
adherence rate (13; 92.9%). Travellers who had been to endemic
countries before showed slightly higher projected adherence rates (107;
78.7%) than inexperienced travellers (47; 73.4%), (p = 0.411).
4. Discussion
Malaria and arboviral infection prevention strategies pose major
challenges in travel medicine [33–35] and repellents play a key role in
prevention. This study was a quantitative approach to provide a better
understanding of the adherence to repellents by travellers and of their
knowledge, attitude, and practice to AVPM in general. Most travellers
in our study intended to use repellents on their trip, however the doses
applied were often too low to provide suﬃcient protection levels.
Travellers to Africa, women and people aged over 40 showed the best
compliance to AVPM.
Looking at the amount of repellent applied, two variables have to be
considered, the total amount of repellent applied and the concentration
of active substance attained on the skin. The total amount of repellent
was used to compare the formulation of the repellents, in this study a
spray versus a lotion. The diﬀerence in quantity applied between the
two repellents was small (0.032mg/cm2) and statistically not sig-
niﬁcant (p=0.389). Accordingly, the formulation (i.e. spray versus
lotion) of the repellent does not seem to have a considerable inﬂuence
on the applied dose.
The concentration of active substance reached on the skin provides
the protection against mosquito bites. Subjects applying the DEET/
Icaridin spray (50% active substance) reached higher average con-
centrations on the skin (0.52 mg/cm2) than subjects applying the
Icaridin lotion (20% active substance, 0.214mg/cm2). However, with
both repellents the average concentration was well below 1mg/cm2,
i.e. the recommended protective level. Our results also show a wide
range and large standard deviations of doses applied, particularly in the
DEET/Icaridin spray group. Only 5 subjects (5%) in the group using the
DEET/Icaridin spray achieved the recommended protective level of
1mg/cm2 versus none of the users of the Icaridin lotion. Furthermore, a
loss of repellent during the application process, especially a residue on
the hands, should be considered and therefore the actual skin con-
centration might be even lower in some cases. Thus, it appears from our
Table 1
Number of travellers intending to travel to diﬀerent travel destinations, sex, mean age, the purpose of their trip, and the number of travellers with previous travel
experience to countries endemic for mosquito borne infections.
Destination Number of Travellers Male Mean Age Purpose of the trip Previous Tripsa
Tourism Business Trip VFR
South America 64 33 (51.5%) 35.9 50 (78.1%) 5 (7.8%) 9 (14.1%) 47 (73.4%)
South East Asia 63 33 (52.4%) 28.7 58 (92.1%) 3 (4.8%) 2 (3.2%) 35 (55.6%)
East Africa 28 14 (50.0%) 35.6 26 (92.9%) 2 (7.1%) 0 20 (71.4%)
Southern Africa 16 6 (37.5%) 45.1 16 (100%) 0 0 14 (87.5%)
West Africa 13 5 (38.5%) 33.9 6 (46.2%) 3 (23.1%) 4 (30.8%) 9 (69.2%)
Central America 12 7 (58.3%) 40.5 11 (91.7%) 1 (8.3%) 0 7 (58.3%)
Middle East 3 1 (33.3%) 41 2 (66.7%) 0 1 (33.3%) 3 (100%)
Australia 1 0 18 1 (100%) 0 0 1 (100%)
Total 200 99 (49.5%) 34.5 170 (85.0%) 14 (7.0%) 16 (8.0%) 136 (68.0%)
a Travellers who had previously visited countries endemic for mosquito borne infections.
Table 2
Mean dose of repellent applied [mg/cm2] (SD).
DEET/Icaridin spray P-value Icaridin lotion P-value
Total 1.04 (0.91) 1.07 (0.65) 0.389
Male 0.84 (0.55) 0.020* 1.00 (0.54) 0.138
Female 1.21 (1.11) 1.15 (0.76)
Age 18–29 years 1.00 (0.99) 0.069 0.95 (0.65) 0.192
Age 30–39 years 0.79 (0.28) 1.11 (0.52)
Age 40+ 1.36 (1.12) 1.22 (0.74)
*p-values< 0.05 are considered signiﬁcant.
Fig. 2. Applied doses of repellents and their active ingredients on the left arm.
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results that this formulation containing just 20% of active substance,
i.e. 20% Icaridin, will not suﬃce as a repellent. Higher concentrations
of Icaridin are indicated.
Subjective repellent tolerability was good and no serious adverse
events were observed, as we expected from previous risk assessments
and from the literature [14,15,21] which shows that topically applied
repellents are generally well tolerated. With regard to cosmetic prop-
erties of the two formulations, the number of subjects reporting “a
sticky feeling on the skin” after the application was only slightly lower
in the Icaridin group compared to the DEET/Icaridin group and sta-
tistically not signiﬁcant. This is interesting as DEET is often described to
leave an oily, greasy or sticky feeling on the skin [4]. Another issue is
the perceived tolerability of repellents by travellers. Some travellers
might fear adverse events after using repellents, which might reduce
the adherence rate. Travellers’ perceived tolerability of repellents is an
area for further research.
The “Knowledge, Attitude, Practices” (KAP) part of the study pro-
vided some relevant data. Only 3% of the subjects said they would
never use repellents on their trip. This number is quite low compared to
other surveys [30–32] and may be due to a bias as participants may
have been zealous as they were seeking pre-travel health advice and
were focused on applying repellents. Those seeking pre-travel advice
have been shown to have a heightened awareness for mosquito borne
infections and to be willing to use preventive measures [36]. The in-
tention of a high proportion of travellers to use repellents may also be a
result of the heightened media attention regarding the spread of mos-
quito-borne infections particularly the ZIKA virus. Some 146 (73.4%) of
the subjects intended to use the repellents less often than every 5 h, i.e.
the frequency of application that is usually recommended. This is an
important ﬁnding especially in conjunction with the results showing
Fig. 3. Distribution of the concentration of active ingredient reached on the skin.
Table 3
Group data and adverse events of repellents.
Repellent DEET/Icaridin spray Icaridin lotion P-valuea
Number 100 100
Mean Age (SD) 34.02 (12.49) 34.93 (13.34)
Male 46 53
Burning on skin 6 6 p=1.000
Redness of skin 1 3 p=0.621
Sticky feeling 48 41 p=0.319
Burning in the airways 4 0 p=0.121
Odour, medianb (IQR) 3.09 (2) 3.09 (0) p= 1.000
Usability, medianc (IQR) 1.35 (1) 1.52 (1) p= 0.098
a p-values are considered exploratory.
b Visual analog scale: 1= unpleasant, 5= pleasant.
c Visual analog scale: 1= easy to use, 5= complicated to use.
Table 4
How often travellers intend to apply repellents per day.
Male (n= 98) Female (n= 101) Total (n= 199)
Never 6 0 6
Once per day 23 22 45
Twice per day 46 49 95
Every 5 h 19 22 41
Every 3 h 4 8 12
Table 5
Mosquito bite prevention measures and the number of travellers who intend to
use them.
Measures Total Male
(n= 99)
Female
(n= 101)
P-value*
Any measure 154 (77.0%) 66 (66.7%) 88 (87.1%) p= 0.001
Long sleeved
clothing
119 (59.5%) 51 (51.5%) 68 (67.3%) p= 0.023
Mosquito net 99 (49.5%) 39 (39.4%) 60 (59.4%) p= 0.005
Light coloured
clothing
39 (19.5%) 16 (16.2%) 23 (22.8%) p= 0.238
Impregnation of
clothes
39 (19.5%) 16 (16.2%) 23 (22.8%) p= 0.238
Air conditioning 25 (12.5%) 14 (14.1%) 11 (10.9%) p= 0.238
Perfumed candlesa 17 (8.5%) 5 (5.1%) 12 (11.9%) p= 0.127
Vitamin Ba 5 (2.5%) 2 (2.0%) 3 (3.0%) p= 1.000
Ultrasonic devicesa 3 (1.5%) 0 3 (2.97%) p= 0.246
Perfumesa 2 (1%) 1 (1.0%) 1 (1.0%) p= 1.000
*p-values are considered exploratory.
a Measures in italics are considered to have no anti-vectorial prevention ef-
ﬁcacy.
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that sub-optimal concentrations of repellents were applied. To com-
pensate low application dosages, repellents could be applied more
frequently and frequent application of low dosages may well provide
reasonable repellent levels. However, it appears that travellers neither
use adequate quantities of repellents nor do they apply them often
enough. Sex and age have a major inﬂuence on the adherence to re-
pellents. Women as well as the oldest age group applied higher doses of
both repellents and also intended to use them more frequently. Young
men applied the lowest doses. This will have an impact on the acqui-
sition of vector-borne infections and may contribute, to some extent, to
the male sex-bias for certain mosquito-borne infections such as malaria
[37,38].
Regarding the other AVPM that the subjects intended to use beside
repellents, travellers to Africa, the continent with the highest risk for
malaria, showed the best adherence. More than 90% of travellers to
Africa intended to use at least one further AVPM additionally to re-
pellents (East Africa 100%, West Africa 92.3%, Southern Africa 87.5%).
Travellers to South America (71.8%), South East Asia (73.0%) and
Central America (58.3%) showed lower projected AVPM adherence
rates. Comparing these results with previous studies, travellers to Africa
showed better projected adherence rates, while the results of travellers
to other destinations were similar [31,39]. Especially the number of
travellers intending to use mosquito nets is highest in Africa (East Africa
82.1%, Southern Africa 81.3%, West Africa 61.5%), possibly because
travellers to these regions might be more aware of malaria.
The most intended AVPM was wearing of long-sleeved clothing
(59.5%). However, it is questionable whether travellers will really wear
long-sleeved clothing permanently in hot temperatures. Only few tra-
vellers (12.5%) intended to use air conditioning and there was no dif-
ference between the travel destinations. Travellers may not be aware
that air conditioning is one of the most eﬀective AVPM. Furthermore,
some travellers still intend to use measures like perfumed candles, vi-
tamin B, ultrasonic devices, and perfumes, although they have been
shown to be ineﬀective [40,41].
The strength of this study was the large number of subjects, 100 per
repellent group, who provided reliable results for the applied amount of
repellents. In our study, the circumstances were close to real life, but
some further diﬀerences in application quantities may be expected
when travellers are using repellents in areas with actual transmission of
vector-borne infections. One weakness of the study is the fact that
travellers were pre-selected, in that they were seeking pre-travel advice
and we may thus have recruited, per se, more cautious, adherent in-
dividuals. The subjects were only interviewed before they were going
on a trip and therefore they could only state which measures they in-
tended to use and this may not reﬂect what actually will be used on the
trip. However, more than half of the subjects had already travelled to
regions endemic for mosquito borne infections and they did not intend
signiﬁcantly better adherence to AVPM than inexperienced travellers.
The only exception was the impregnation of clothes, which seems to be
better known among experienced travellers.
5. Conclusions
Even travellers who consciously seek out pre-travel advice and who
are keen to use anti-mosquito measures do not apply adequate, pro-
tective quantities of repellent. Women and those aged over 40 years are
the most likely adherent users of repellents and other AVPM. Most
manufacturers give only sparse recommendations for the quantitative
use of repellents, particularly on the repellent packaging, and many
advise not to use them more than twice a day. It would be advantageous
to improve these recommendations by suggesting an optimal dosage
and frequency of application. Formulations containing only 20% or less
active ingredient do not provide a suﬃcient protection against mos-
quito bites. Travellers going to areas endemic for mosquito borne in-
fections should use repellents with at least 30% or more of active in-
gredient.
The pre-travel health advice consultation should provide more in-
formation on the application quantity and correct use of repellents, e.g.
the skin should be completely wetted after application. Furthermore,
pre-travel advice should also provide some information about possible
adverse reactions after repellent application, such as a burning sensa-
tion on the skin, reddening of the skin, burning sensation in the air-
ways, to allay fears of adverse events, which may decrease the ad-
herence rates. Particular attention in the pre-travel advice consultation
should be given to young male travellers, the group with the lowest
adherence rates to AVPM.
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